These results pave the way for pivotal trials in Crohn's disease and ulcerative colitis, as well as, potentially, other Immunological and fibrotic indications beyond, in collaboration with our partner, Sanofi (NASDAQ:SNY)." Wrapping Up 2024 With a Strong Finish for a Solid Year Tevas Q4 2024 results were relatively strong
What is the GLP-1 metabolic advantage
GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide) commonly cause headaches during initial weeks or after dose escalation due to altered gastric emptying, hydration changes, and metabolic adjustments
These profound effects on brain structure and function position Dihexa as a promising candidate for cognitive enhancement and the regeneration of neural networks compromised by injury or disease
Startups and specialty stores in cities like Bengaluru and Mumbai are introducing yerba mate through wellness cafes and online platforms
CASE REPORT A 62-year-old woman presented with acute onset abdominal pain and bloody stools
